Breaking News Instant updates and real-time market news.

WMGI

Wright Medical

$22.00

1.2 (5.77%)

, SYK

Stryker

$212.78

-3.5 (-1.62%)

07:06
11/04/19
11/04
07:06
11/04/19
07:06

Stryker to acquire Wright Medical for $30.75 per share in cash

Stryker (SYK) announced a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (WMGI) for $30.75 per share, or a total equity value of approximately $4B and a total enterprise value of approximately $5.4B. Wright Medical, which was founded in 1950, is a global medical device company focused on extremities and biologics. Wright Medical brings a highly complementary product portfolio and customer base to Stryker's trauma and extremities business. With global sales approaching $1B, Wright Medical is a recognized leader in the upper extremities, lower extremities and biologics markets, which are among the fastest growing segments in orthopaedics. Wright Medical's leading upper extremity portfolio and advanced preoperative planning technology will significantly add to Stryker's offering. Additionally, Wright Medical's lower extremity and biologics will complement Stryker's portfolio and strengthen the company's position in this high-growth segment. Under the terms of the agreement, Stryker will commence a tender offer for all outstanding ordinary shares of Wright Medical for $30.75 per share, in cash. The boards of directors of both Stryker and Wright Medical have approved the transaction. The closing of the transaction is subject to receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an extraordinary general meeting of Wright Medical shareholders, completion of the tender offer and other customary closing conditions. The acquisition of Wright Medical is expected to close in the second half of 2020 and is expected to have no impact to Stryker's net earnings per diluted share and adjusted net earnings per diluted share in 2019. There is no change to Stryker's previously announced expected adjusted net earnings per diluted share for the full year, which is a range of $8.20 - $8.25. Assuming a September 30, 2020 closing, the transaction is expected to have no impact to Stryker's adjusted net earnings per share in 2020, 10c dilution in 2021 and will be accretive thereafter.

WMGI

Wright Medical

$22.00

1.2 (5.77%)

SYK

Stryker

$212.78

-3.5 (-1.62%)

WMGI Wright Medical
$22.00

1.2 (5.77%)

08/16/19
PIPR
08/16/19
NO CHANGE
Target $27
PIPR
Overweight
Wright Medical pullback brings good entry point, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says the recent pullback in shares of Wright Medical represents a good entry point. After hosting investor meetings with management this week, the analyst recommends buying the stock at these levels. Wright has dismissed all but one of their troubled lower extremity distributors and started selling through its own direct reps in these territories as of August 1, O'Brien tells investors in a research note. With the upper extremities business still growing quickly and a commitment to the EBITDA metrics laid out before the issue surfaced, "there is a lot to like here," says the analyst. He keeps an Overweight rating on the shares with a $27 price target.
09/09/19
BOFA
09/09/19
NO CHANGE
BOFA
Generac added to Endeavor List, Wright Medical removed at BofA/Merrill
11/03/19
STFL
11/03/19
NO CHANGE
STFL
Stifel agrees with report saying Wright Medical may be evaluating options
Stifel analyst Mathew Blackman, who has a Buy rating and $30 price target on Wright Medical Group (WMGI), said that Bloomberg reported late Friday that Wright Medical had engaged financial advisers to explore a potential sale of the company. While the analyst noted that it is impossible to confirm that report, he sees "legitimate reasons to believe the company is potentially evaluating strategic options," including its significant share underperformance, lack of a clear CEO succession plan, and that the shares are "undervalued relative to the company's leading position in attractive end markets with a robust profitability profile."
11/04/19
CANT
11/04/19
NO CHANGE
Target $28
CANT
Overweight
Wright Medical buyout long part of investment thesis, says Cantor Fitzgerald
A potential takeout has long been part of Wright Medical Group's investment thesis since current CEO Bob Palmisano took over leadership of the company in 2011, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note. As such, he is "somewhat hesitant" to believe that Friday's report from Bloomberg regarding a potential sale is different from the prior occasions. With that said, the analyst says Medtech transactions over the last five years suggest a multiple of four-to-five times forward sales. Wright is an attractive asset, but there are likely several considerations for potential buyers, says Bijou, who keeps an Overweight rating on the shares with a $28 price target.
SYK Stryker
$212.78

-3.5 (-1.62%)

07/26/19
CANT
07/26/19
NO CHANGE
Target $230
CANT
Overweight
Stryker price target raised to $230 from $190 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Stryker to $230 from $190 citing the company's "impressive" Q2 results. The analyst, however, thinks investor expectations for the stock "remain lofty." He keeps a Neutral rating on the shares.
07/26/19
ADAM
07/26/19
NO CHANGE
Target $233
ADAM
Buy
Stryker price target raised to $233 from $195 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Stryker to $233 from $195 following strong Q2 results. The analyst said there was momentum across the entire portfolio and operationally, its earnings reflected strong sales growth and operating expense improvements. Rose reiterated his Buy rating on Stryker shares.
09/04/19
PIPR
09/04/19
NO CHANGE
PIPR
Overweight
Piper says robotics entry can accelerate Stryker's spine implant pull-through
After Stryker announced the purchase of Mobius Imaging and Cardan Robotics for $370M upfront and $130M in potential future milestones, Piper Jaffray analyst Matt O'Brien said he believes that having a robotics offering should accelerate implant pull-through for the company's Spine division. The analyst, who also sees the deals helping Stryker to present a more complete offering to customers once commercially available, keeps an Overweight rating on the stock.
09/05/19
ADAM
09/05/19
NO CHANGE
Target $233
ADAM
Buy
Stryker M&A activity viewed positively, says Canaccord
Canaccord analyst Kyle Rose noted Stryker agreed to acquire an imaging and robotics company which put them deeper into the spine business and complement their broader portfolio of robotic and navigation offerings which Rose believes is the future of spine surgery. Rose views the moves positively and views Stryker as a compelling asset. Rose reiterated his Buy rating and $233 price target on Stryker shares.

TODAY'S FREE FLY STORIES

OEZVY

Verbund

$0.00

(0.00%)

05:28
12/12/19
12/12
05:28
12/12/19
05:28
Upgrade
Verbund rating change  »

Verbund upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$83.17

0.81 (0.98%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Autoliv rating change  »

Autoliv upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AMGN

Amgen

$233.96

0.14 (0.06%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Hot Stocks
Amgen, UCB announce EC approval of EVENITY »

Amgen and UCB announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$28.03

0.14 (0.50%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Kroger rating change  »

Kroger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
BMW rating change  »

BMW upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$49.60

0.43 (0.87%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVKIF

Evonik

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Upgrade
Evonik rating change  »

Evonik upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Downgrade
Solvay rating change  »

Solvay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:21
12/12/19
12/12
05:21
12/12/19
05:21
Upgrade
Solvay rating change  »

Solvay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$86.59

0.56 (0.65%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Upgrade
Starbucks rating change  »

Starbucks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWI

SolarWinds

$18.28

0.1 (0.55%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Recommendations
SolarWinds analyst commentary  »

SolarWinds remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAKE

Cheesecake Factory

$40.73

-0.77 (-1.86%)

05:14
12/12/19
12/12
05:14
12/12/19
05:14
Initiation
Cheesecake Factory initiated  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXRH

Texas Roadhouse

$57.25

0.55 (0.97%)

05:13
12/12/19
12/12
05:13
12/12/19
05:13
Initiation
Texas Roadhouse initiated  »

Texas Roadhouse initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DRI

Darden

$117.44

-1.15 (-0.97%)

05:11
12/12/19
12/12
05:11
12/12/19
05:11
Initiation
Darden initiated  »

Darden initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EAT

Brinker

$41.12

-0.225 (-0.54%)

05:09
12/12/19
12/12
05:09
12/12/19
05:09
Initiation
Brinker initiated  »

Brinker initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$21.95

-0.065 (-0.30%)

05:08
12/12/19
12/12
05:08
12/12/19
05:08
Initiation
Bloomin' Brands initiated  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.62

0.62 (6.89%)

05:05
12/12/19
12/12
05:05
12/12/19
05:05
Downgrade
Bright Scholar rating change  »

Bright Scholar downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$88.09

0.165 (0.19%)

04:59
12/12/19
12/12
04:59
12/12/19
04:59
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

MD

Mednax

$26.75

1.975 (7.97%)

04:56
12/12/19
12/12
04:56
12/12/19
04:56
Upgrade
Mednax rating change  »

Mednax upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNFT

Genfit

$15.38

-0.805 (-4.97%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst Rahimi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

WCN

Waste Connections

$90.15

-0.03 (-0.03%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Waste Connections participates in a conference call with UBS »

Environmental Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
JPMorgan software technology analyst to hold an analyst/industry conference call »

Software Technology…

DNOW

NOW Inc.

$11.22

0.195 (1.77%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
NOW Inc. management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Feb

MASI

Masimo

$154.28

1.62 (1.06%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Masimo management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

04:55
12/12/19
12/12
04:55
12/12/19
04:55
General news
PPI-FD to be reported at 08:30 »

November PPI-FD will be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.